Found: 5
Select item for more details and to access through your institution.
Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist.
- Published in:
- Pharmacology Research & Perspectives, 2023, v. 11, n. 4, p. 1, doi. 10.1002/prp2.1112
- By:
- Publication type:
- Article
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 11, p. 827, doi. 10.1007/s40261-023-01310-6
- By:
- Publication type:
- Article
Pharmacokinetics‐Based Pediatric Dose Evaluation and Optimization Using Saliva – A Case Study.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 7, p. 810, doi. 10.1002/jcph.2428
- By:
- Publication type:
- Article
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 7, p. 1220, doi. 10.1111/cts.13525
- By:
- Publication type:
- Article
Multiple‐ascending doses of ACT‐1014‐6470, an oral complement factor 5a receptor 1 (C5a<sub>1</sub> receptor) antagonist: Tolerability, pharmacokinetics and target engagement.
- Published in:
- British Journal of Clinical Pharmacology, 2023, v. 89, n. 1, p. 380, doi. 10.1111/bcp.15508
- By:
- Publication type:
- Article